Inclusion Criteria:

   - Age 7 years or older

   - Prior first allogeneic stem cell transplant, with any graft source, donor type, and
   GVHD prophylaxis.

   - Diagnosis of chronic GVHD according to the criteria of the diagnosis and scoring group
   of the NIH consensus conference (Patient must have at least one diagnostic
   manifestation of chronic GVHD or one distinctive manifestation with pathological
   confirmation of the diagnosis. Concurrent acute GVHD manifestations will be allowed as
   long as at least one classic chronic manifestation is present.)

   - Initiation of a new systemic treatment for chronic GVHD in the past 4 weeks or
   anticipated within the next 4 weeks. Systemic treatment is defined as any medication
   or intervention that has intended systemic effects, including extracorporeal
   photopheresis, regardless of prior lines of therapy or prior treatment with the
   agent(s). If a patient is restarting a treatment to which they were previously
   exposed, they must have been off of it for at least 4 weeks before restarting.

   - No evidence of persistent or progressive malignancy at the time of enrollment

   - Evaluation at the transplant center at the time of study enrollment, and agreement to
   be re-evaluated at the transplant center up to four subsequent times: at 3 months, 6
   months, and 18 months after enrollment and once if another treatment is added for
   chronic GVHD.

   - Signed, informed consent

Exclusion Criteria:

   - Inability to comply with study procedures

   - Complete resolution of chronic GVHD at the time of enrollment (patient must have some
   measurable chronic GVHD activity)